Ex-Metacrine chief Preston Klassen recharges at microRNA biotech; Allogene begins search for a CFO
→ Preston Klassen has mapped out his next destination as president and R&D chief of microRNA developer Regulus Therapeutics. Klassen was the CEO of Metacrine, a biotech co-founded and chaired by Rich Heyman that was ensnarled in toxicity issues with its NASH program. Metacrine would hand out pink slips to half its workforce before a merger with Equillium that ultimately didn’t materialize. Earlier, Klassen was CMO and US president of Sanifit and then led R&D at Arena Pharmaceuticals. Regulus also welcomed Allergan vet Curtis Monnig as VP of CMC, the same position he previously held at January Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
